The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with doxorubicin

The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with doxorubicin

Abstract Background Empagliflozin (EMPA), a selective inhibitor of the sodium glucose co-transporter 2, reduced the risk of hospitalization for heart failure and cardiovascular death in type 2 diabetic patients in the EMPA‐REG OUTCOME trial. Recent trials evidenced several cardio-renal benefits of E...

Full description

Bibliographic Details
Main Authors: Vincenzo Quagliariello, Michelino De Laurentiis, Domenica Rea, Antonio Barbieri, Maria Gaia Monti, Andreina Carbone, Andrea Paccone, Lucia Altucci, Mariarosaria Conte, Maria Laura Canale, Gerardo Botti, Nicola Maurea
Format: Article
Language:English
Published: BMC 2021-07-01
Series:Cardiovascular Diabetology
Subjects:
EMPA
Cardio-Oncology
Doxorubicin
Inflammation
Interleukins
Online Access:https://doi.org/10.1186/s12933-021-01346-y

Internet

https://doi.org/10.1186/s12933-021-01346-y

Similar Items